Which has better earnings & valuation, NTLA or AGMB?

AgomAb Therapeutics has lower revenue, but higher earnings than Intellia Therapeutics. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Intellia Therapeutics $67.67M 26.26 -$412.69M -$3.36 N/A AgomAb Therapeutics N/A N/A -$70.77M N/A N/A

Does the media refer more to NTLA or AGMB?

In the previous week, Intellia Therapeutics had 2 more articles in the media than AgomAb Therapeutics. MarketBeat recorded 4 mentions for Intellia Therapeutics and 2 mentions for AgomAb Therapeutics. Intellia Therapeutics' average media sentiment score of 1.10 beat AgomAb Therapeutics' score of 0.13 indicating that Intellia Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Intellia Therapeutics 3 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive AgomAb Therapeutics 0 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Which has stronger valuation & earnings, RXRX or AGMB?

AgomAb Therapeutics has lower revenue, but higher earnings than Recursion Pharmaceuticals. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Recursion Pharmaceuticals $74.68M 24.66 -$644.76M -$1.04 N/A AgomAb Therapeutics N/A N/A -$70.77M N/A N/A

Does the media favor RXRX or AGMB?

In the previous week, Recursion Pharmaceuticals had 3 more articles in the media than AgomAb Therapeutics. MarketBeat recorded 5 mentions for Recursion Pharmaceuticals and 2 mentions for AgomAb Therapeutics. Recursion Pharmaceuticals' average media sentiment score of 0.66 beat AgomAb Therapeutics' score of 0.13 indicating that Recursion Pharmaceuticals is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Recursion Pharmaceuticals 3 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive AgomAb Therapeutics 0 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Which has better earnings and valuation, SNDX or AGMB?

AgomAb Therapeutics has lower revenue, but higher earnings than Syndax Pharmaceuticals. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Syndax Pharmaceuticals $172.35M 10.63 -$285.42M -$2.51 N/A AgomAb Therapeutics N/A N/A -$70.77M N/A N/A

Does the media prefer SNDX or AGMB?

In the previous week, Syndax Pharmaceuticals had 4 more articles in the media than AgomAb Therapeutics. MarketBeat recorded 6 mentions for Syndax Pharmaceuticals and 2 mentions for AgomAb Therapeutics. Syndax Pharmaceuticals' average media sentiment score of 1.43 beat AgomAb Therapeutics' score of 0.13 indicating that Syndax Pharmaceuticals is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Syndax Pharmaceuticals 4 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive AgomAb Therapeutics 0 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Which has preferable earnings & valuation, AGMB or ANAB?

AnaptysBio has higher revenue and earnings than AgomAb Therapeutics. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio AgomAb Therapeutics N/A N/A -$70.77M N/A N/A AnaptysBio $234.60M 7.25 -$13.23M -$1.08 N/A

Is AGMB or ANAB more profitable?

AgomAb Therapeutics has a net margin of 0.00% compared to AnaptysBio's net margin of -11.53%. Company Net Margins Return on Equity Return on Assets AgomAb Therapeutics N/A N/A N/A AnaptysBio -11.53% N/A -7.75%

Does the media favor AGMB or ANAB?

In the previous week, AnaptysBio had 5 more articles in the media than AgomAb Therapeutics. MarketBeat recorded 7 mentions for AnaptysBio and 2 mentions for AgomAb Therapeutics. AnaptysBio's average media sentiment score of 1.28 beat AgomAb Therapeutics' score of 0.13 indicating that AnaptysBio is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment AgomAb Therapeutics 0 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral AnaptysBio 5 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Which has stronger earnings and valuation, AGMB or VIR?

AgomAb Therapeutics has higher earnings, but lower revenue than Vir Biotechnology. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio AgomAb Therapeutics N/A N/A -$70.77M N/A N/A Vir Biotechnology $68.56M 28.26 -$437.99M -$1.86 N/A

Does the media refer more to AGMB or VIR?

In the previous week, Vir Biotechnology had 5 more articles in the media than AgomAb Therapeutics. MarketBeat recorded 7 mentions for Vir Biotechnology and 2 mentions for AgomAb Therapeutics. Vir Biotechnology's average media sentiment score of 1.07 beat AgomAb Therapeutics' score of 0.13 indicating that Vir Biotechnology is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment AgomAb Therapeutics 0 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Vir Biotechnology 4 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

AgomAb Therapeutics (AGMB) Competitors

$14.83 +1.17 (+8.57%)

As of 09/3/2026 04:00 PM Eastern

Compare

AGMB vs. NTLA, RXRX, SNDX, ANAB, and VIR

Should you buy AgomAb Therapeutics stock or one of its competitors? AgomAb Therapeutics's main competitors and comparable companies include Intellia Therapeutics (NTLA), Recursion Pharmaceuticals (RXRX), Syndax Pharmaceuticals (SNDX), AnaptysBio (ANAB), and Vir Biotechnology (VIR). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "biotechnology" industry.

How does AgomAb Therapeutics compare to Intellia Therapeutics?

Intellia Therapeutics (NASDAQ:NTLA) and AgomAb Therapeutics (NASDAQ:AGMB) are both small-cap healthcare companies, but which is the better business? We will contrast the two companies based on the strength of their profitability, earnings, institutional ownership, dividends, valuation, media sentiment, analyst recommendations and risk.

AgomAb Therapeutics has a net margin of 0.00% compared to Intellia Therapeutics' net margin of -672.16%. AgomAb Therapeutics' return on equity of 0.00% beat Intellia Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Intellia Therapeutics	-672.16%	-57.79%	-47.29%
AgomAb Therapeutics	N/A	N/A	N/A

Intellia Therapeutics presently has a consensus price target of $21.15, suggesting a potential upside of 66.82%. AgomAb Therapeutics has a consensus price target of $37.50, suggesting a potential upside of 152.87%. Given AgomAb Therapeutics' stronger consensus rating and higher probable upside, analysts plainly believe AgomAb Therapeutics is more favorable than Intellia Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Intellia Therapeutics	4 Sell rating(s)	8 Hold rating(s)	10 Buy rating(s)	1 Strong Buy rating(s)	2.35
AgomAb Therapeutics	0 Sell rating(s)	1 Hold rating(s)	7 Buy rating(s)	0 Strong Buy rating(s)	2.88

In the previous week, Intellia Therapeutics had 2 more articles in the media than AgomAb Therapeutics. MarketBeat recorded 4 mentions for Intellia Therapeutics and 2 mentions for AgomAb Therapeutics. Intellia Therapeutics' average media sentiment score of 1.10 beat AgomAb Therapeutics' score of 0.13 indicating that Intellia Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Intellia Therapeutics	3 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
AgomAb Therapeutics	0 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

88.8% of Intellia Therapeutics shares are held by institutional investors. 3.5% of Intellia Therapeutics shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

AgomAb Therapeutics has lower revenue, but higher earnings than Intellia Therapeutics.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Intellia Therapeutics	$67.67M	26.26	-$412.69M	-$3.36	N/A
AgomAb Therapeutics	N/A	N/A	-$70.77M	N/A	N/A

Summary

Intellia Therapeutics beats AgomAb Therapeutics on 7 of the 13 factors compared between the two stocks.

How does AgomAb Therapeutics compare to Recursion Pharmaceuticals?

Recursion Pharmaceuticals (NASDAQ:RXRX) and AgomAb Therapeutics (NASDAQ:AGMB) are both small-cap healthcare companies, but which is the better investment? We will contrast the two companies based on the strength of their dividends, institutional ownership, valuation, profitability, earnings, risk, analyst recommendations and media sentiment.

AgomAb Therapeutics has lower revenue, but higher earnings than Recursion Pharmaceuticals.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Recursion Pharmaceuticals	$74.68M	24.66	-$644.76M	-$1.04	N/A
AgomAb Therapeutics	N/A	N/A	-$70.77M	N/A	N/A

89.1% of Recursion Pharmaceuticals shares are held by institutional investors. 6.7% of Recursion Pharmaceuticals shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

AgomAb Therapeutics has a net margin of 0.00% compared to Recursion Pharmaceuticals' net margin of -945.94%. AgomAb Therapeutics' return on equity of 0.00% beat Recursion Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Recursion Pharmaceuticals	-945.94%	-50.41%	-38.25%
AgomAb Therapeutics	N/A	N/A	N/A

In the previous week, Recursion Pharmaceuticals had 3 more articles in the media than AgomAb Therapeutics. MarketBeat recorded 5 mentions for Recursion Pharmaceuticals and 2 mentions for AgomAb Therapeutics. Recursion Pharmaceuticals' average media sentiment score of 0.66 beat AgomAb Therapeutics' score of 0.13 indicating that Recursion Pharmaceuticals is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Recursion Pharmaceuticals	3 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
AgomAb Therapeutics	0 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Recursion Pharmaceuticals currently has a consensus price target of $8.06, indicating a potential upside of 134.30%. AgomAb Therapeutics has a consensus price target of $37.50, indicating a potential upside of 152.87%. Given AgomAb Therapeutics' stronger consensus rating and higher probable upside, analysts plainly believe AgomAb Therapeutics is more favorable than Recursion Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Recursion Pharmaceuticals	1 Sell rating(s)	2 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.20
AgomAb Therapeutics	0 Sell rating(s)	1 Hold rating(s)	7 Buy rating(s)	0 Strong Buy rating(s)	2.88

Summary

AgomAb Therapeutics beats Recursion Pharmaceuticals on 7 of the 12 factors compared between the two stocks.

How does AgomAb Therapeutics compare to Syndax Pharmaceuticals?

Syndax Pharmaceuticals (NASDAQ:SNDX) and AgomAb Therapeutics (NASDAQ:AGMB) are both small-cap healthcare companies, but which is the better business? We will contrast the two companies based on the strength of their analyst recommendations, earnings, risk, valuation, profitability, media sentiment, institutional ownership and dividends.

AgomAb Therapeutics has lower revenue, but higher earnings than Syndax Pharmaceuticals.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Syndax Pharmaceuticals	$172.35M	10.63	-$285.42M	-$2.51	N/A
AgomAb Therapeutics	N/A	N/A	-$70.77M	N/A	N/A

In the previous week, Syndax Pharmaceuticals had 4 more articles in the media than AgomAb Therapeutics. MarketBeat recorded 6 mentions for Syndax Pharmaceuticals and 2 mentions for AgomAb Therapeutics. Syndax Pharmaceuticals' average media sentiment score of 1.43 beat AgomAb Therapeutics' score of 0.13 indicating that Syndax Pharmaceuticals is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Syndax Pharmaceuticals	4 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
AgomAb Therapeutics	0 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

AgomAb Therapeutics has a net margin of 0.00% compared to Syndax Pharmaceuticals' net margin of -87.52%. AgomAb Therapeutics' return on equity of 0.00% beat Syndax Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Syndax Pharmaceuticals	-87.52%	-372.94%	-39.11%
AgomAb Therapeutics	N/A	N/A	N/A

Syndax Pharmaceuticals currently has a consensus price target of $42.30, indicating a potential upside of 104.55%. AgomAb Therapeutics has a consensus price target of $37.50, indicating a potential upside of 152.87%. Given AgomAb Therapeutics' stronger consensus rating and higher probable upside, analysts plainly believe AgomAb Therapeutics is more favorable than Syndax Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Syndax Pharmaceuticals	1 Sell rating(s)	0 Hold rating(s)	11 Buy rating(s)	0 Strong Buy rating(s)	2.83
AgomAb Therapeutics	0 Sell rating(s)	1 Hold rating(s)	7 Buy rating(s)	0 Strong Buy rating(s)	2.88

Summary

AgomAb Therapeutics beats Syndax Pharmaceuticals on 6 of the 10 factors compared between the two stocks.

How does AgomAb Therapeutics compare to AnaptysBio?

AgomAb Therapeutics (NASDAQ:AGMB) and AnaptysBio (NASDAQ:ANAB) are both small-cap healthcare companies, but which is the better business? We will compare the two companies based on the strength of their institutional ownership, media sentiment, profitability, risk, earnings, analyst recommendations, dividends and valuation.

AgomAb Therapeutics presently has a consensus target price of $37.50, indicating a potential upside of 152.87%. AnaptysBio has a consensus target price of $79.85, indicating a potential upside of 38.96%. Given AgomAb Therapeutics' stronger consensus rating and higher probable upside, equities research analysts clearly believe AgomAb Therapeutics is more favorable than AnaptysBio.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
AgomAb Therapeutics	0 Sell rating(s)	1 Hold rating(s)	7 Buy rating(s)	0 Strong Buy rating(s)	2.88
AnaptysBio	1 Sell rating(s)	3 Hold rating(s)	11 Buy rating(s)	0 Strong Buy rating(s)	2.67

In the previous week, AnaptysBio had 5 more articles in the media than AgomAb Therapeutics. MarketBeat recorded 7 mentions for AnaptysBio and 2 mentions for AgomAb Therapeutics. AnaptysBio's average media sentiment score of 1.28 beat AgomAb Therapeutics' score of 0.13 indicating that AnaptysBio is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
AgomAb Therapeutics	0 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
AnaptysBio	5 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

AgomAb Therapeutics has a net margin of 0.00% compared to AnaptysBio's net margin of -11.53%.

Company	Net Margins	Return on Equity	Return on Assets
AgomAb Therapeutics	N/A	N/A	N/A
AnaptysBio	-11.53%	N/A	-7.75%

AnaptysBio has higher revenue and earnings than AgomAb Therapeutics.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
AgomAb Therapeutics	N/A	N/A	-$70.77M	N/A	N/A
AnaptysBio	$234.60M	7.25	-$13.23M	-$1.08	N/A

Summary

AnaptysBio beats AgomAb Therapeutics on 5 of the 9 factors compared between the two stocks.

How does AgomAb Therapeutics compare to Vir Biotechnology?

AgomAb Therapeutics (NASDAQ:AGMB) and Vir Biotechnology (NASDAQ:VIR) are both small-cap healthcare companies, but which is the better investment? We will compare the two companies based on the strength of their institutional ownership, valuation, risk, profitability, dividends, earnings, analyst recommendations and media sentiment.

In the previous week, Vir Biotechnology had 5 more articles in the media than AgomAb Therapeutics. MarketBeat recorded 7 mentions for Vir Biotechnology and 2 mentions for AgomAb Therapeutics. Vir Biotechnology's average media sentiment score of 1.07 beat AgomAb Therapeutics' score of 0.13 indicating that Vir Biotechnology is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
AgomAb Therapeutics	0 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Vir Biotechnology	4 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

AgomAb Therapeutics has a net margin of 0.00% compared to Vir Biotechnology's net margin of -638.88%. AgomAb Therapeutics' return on equity of 0.00% beat Vir Biotechnology's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
AgomAb Therapeutics	N/A	N/A	N/A
Vir Biotechnology	-638.88%	-29.99%	-23.62%

AgomAb Therapeutics has higher earnings, but lower revenue than Vir Biotechnology.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
AgomAb Therapeutics	N/A	N/A	-$70.77M	N/A	N/A
Vir Biotechnology	$68.56M	28.26	-$437.99M	-$1.86	N/A

AgomAb Therapeutics currently has a consensus target price of $37.50, indicating a potential upside of 152.87%. Vir Biotechnology has a consensus target price of $21.57, indicating a potential upside of 88.40%. Given AgomAb Therapeutics' higher probable upside, research analysts clearly believe AgomAb Therapeutics is more favorable than Vir Biotechnology.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
AgomAb Therapeutics	0 Sell rating(s)	1 Hold rating(s)	7 Buy rating(s)	0 Strong Buy rating(s)	2.88
Vir Biotechnology	1 Sell rating(s)	0 Hold rating(s)	6 Buy rating(s)	1 Strong Buy rating(s)	2.88

65.3% of Vir Biotechnology shares are owned by institutional investors. 2.9% of Vir Biotechnology shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

Summary

AgomAb Therapeutics and Vir Biotechnology tied by winning 6 of the 12 factors compared between the two stocks.

Get AgomAb Therapeutics News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding AGMB and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

AGMB vs. The Competition

Export

Metric	AgomAb Therapeutics	Biotechnology Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$494.99M	$4.03B	$7.26B	$12.73B
Dividend Yield	N/A	3.60%	2.53%	8.86%
P/E Ratio	N/A	12.66	273.29	25.38
Price / Sales	N/A	1,309.08	613.45	97.56
Price / Cash	N/A	106.87	77.82	52.26
Price / Book	1.74	16.29	12.89	6.14
Net Income	-$70.77M	-$22.72M	$3.47B	$349.01M
7 Day Performance	12.60%	0.34%	0.60%	-0.27%
1 Month Performance	0.68%	8.52%	5.73%	0.68%
1 Year Performance	N/A	52.66%	25.35%	14.84%

AgomAb Therapeutics Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
AGMB AgomAb Therapeutics	3.2773 of 5 stars	$14.83 +8.6%	$37.50 +152.9%	N/A	$494.99M	N/A	N/A	62	News Coverage High Trading Volume
NTLA Intellia Therapeutics	2.8388 of 5 stars	$13.51 +7.6%	$21.15 +56.6%	+8.3%	$1.76B	$67.67M	N/A	600	Positive News
RXRX Recursion Pharmaceuticals	1.6834 of 5 stars	$3.56 +9.5%	$8.06 +126.4%	-25.7%	$1.74B	$74.68M	N/A	400	Insider Trade
SNDX Syndax Pharmaceuticals	3.0876 of 5 stars	$19.92 +1.8%	$41.55 +108.6%	+28.2%	$1.73B	$172.35M	N/A	110	Positive News
ANAB AnaptysBio	3.0493 of 5 stars	$58.37 -0.1%	$80.00 +37.1%	+155.0%	$1.73B	$234.60M	N/A	100	Positive News

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:AGMB) was last updated on 9/4/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

AgomAb Therapeutics (AGMB) Competitors

AGMB vs. NTLA, RXRX, SNDX, ANAB, and VIR

How does AgomAb Therapeutics compare to Intellia Therapeutics?

Summary

How does AgomAb Therapeutics compare to Recursion Pharmaceuticals?

Summary

How does AgomAb Therapeutics compare to Syndax Pharmaceuticals?

Summary

How does AgomAb Therapeutics compare to AnaptysBio?

Summary

How does AgomAb Therapeutics compare to Vir Biotechnology?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

AGMB vs. The Competition

AgomAb Therapeutics Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

AgomAb Therapeutics (AGMB) Competitors

AGMB vs. NTLA, RXRX, SNDX, ANAB, and VIR

How does AgomAb Therapeutics compare to Intellia Therapeutics?

Is NTLA or AGMB more profitable?

Do analysts prefer NTLA or AGMB?

Does the media refer more to NTLA or AGMB?

Do institutionals and insiders hold more shares of NTLA or AGMB?

Which has better earnings & valuation, NTLA or AGMB?

Summary

How does AgomAb Therapeutics compare to Recursion Pharmaceuticals?

Which has stronger valuation & earnings, RXRX or AGMB?

Do insiders & institutionals believe in RXRX or AGMB?

Is RXRX or AGMB more profitable?

Does the media favor RXRX or AGMB?

Do analysts recommend RXRX or AGMB?

Summary

How does AgomAb Therapeutics compare to Syndax Pharmaceuticals?

Which has better earnings and valuation, SNDX or AGMB?

Does the media prefer SNDX or AGMB?

Is SNDX or AGMB more profitable?

Do analysts rate SNDX or AGMB?

Summary

How does AgomAb Therapeutics compare to AnaptysBio?

Do analysts recommend AGMB or ANAB?

Does the media favor AGMB or ANAB?

Is AGMB or ANAB more profitable?

Which has preferable earnings & valuation, AGMB or ANAB?

Summary

How does AgomAb Therapeutics compare to Vir Biotechnology?

Does the media refer more to AGMB or VIR?

Is AGMB or VIR more profitable?

Which has stronger earnings and valuation, AGMB or VIR?

Do analysts recommend AGMB or VIR?

Do insiders and institutionals believe in AGMB or VIR?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

AGMB vs. The Competition

AgomAb Therapeutics Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools